|
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENSG00000112715 |
Summary for VEGFA |
Gene summary |
| Gene information | Ensembl ID | ENSG00000112715 | Gene symbol | VEGFA |
| Gene name | vascular endothelial growth factor A | |
| HGNC | 12680 | |
| Entrez ID | 7422 | |
| Gene type | protein_coding | |
| Synonyms | VEGFA|VEGF-A|VPF | |
| UniProtAcc | P15692 |
Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000112715 | VEGFA | DB00112 | Bevacizumab | BiotechDrug |
| ENSG00000112715 | VEGFA | DB01017 | Minocycline | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB01120 | Gliclazide | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB01136 | Carvedilol | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB01270 | Ranibizumab | BiotechDrug |
| ENSG00000112715 | VEGFA | DB03088 | Pidolic acid | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB04895 | Pegaptanib | BiotechDrug |
| ENSG00000112715 | VEGFA | DB05294 | Vandetanib | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB05434 | ABT-510 | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB05890 | Veglin | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB05932 | Denibulin | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB05969 | SNS-032 | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB06642 | Bevasiranib | BiotechDrug |
| ENSG00000112715 | VEGFA | DB06779 | Dalteparin | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB08885 | Aflibercept | BiotechDrug |
| ENSG00000112715 | VEGFA | DB09301 | Chondroitin sulfate | SmallMoleculeDrug |
| ENSG00000112715 | VEGFA | DB10772 | Foreskin keratinocyte (neonatal) | BiotechDrug |
| ENSG00000112715 | VEGFA | DB14864 | Brolucizumab | BiotechDrug |
| ENSG00000112715 | VEGFA | DB15303 | Faricimab | BiotechDrug |
Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
| ENSG00000112715 | VEGFA | DB00112 | Bevacizumab | BiotechDrug | Brain Tumors,Treat Cervical Cancer,Colon Cancer,Rectal Cancer, Renal Cell Cancer (RCC),Non-Small Cell Lung Cancer,Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| ENSG00000112715 | VEGFA | DB05294 | Vandetanib | SmallMoleculeDrug | Thyroid Cancer |
| ENSG00000112715 | VEGFA | DB08885 | Aflibercept | BiotechDrug | Colon Cancer,Rectal Cancer |
Top |
Structure and expression level for VEGFA |
AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure.∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
Landscape of gene expressions across multiple cancer types. |
Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| VEGFA | 7.87e+03 | 1.03e+00 | 1.73e-01 | 5.92e+00 | 3.32e-09 | 1.80e-08 | HNSC |
Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| VEGFA | 6.47e+03 | 2.03e+00 | 2.77e-01 | 7.31e+00 | 2.71e-13 | 1.45e-11 | READ |
Top |
Sex-biased somatic mutation for VEGFA |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for VEGFA |
Landscape of DNA methylation across multiple cancer types. |
Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BLCA | cg00539360 | chr6:43769399 | CGI:chr6:43769895-43772115 | promoter | 6.83e-01 | 5.68e-01 | 2.91e+00 | 3.64e-03 | 6.32e-03 | 1.15e-01 |
| ESCA | cg18022921 | chr6:43769236 | CGI:chr6:43769895-43772115 | promoter | 6.28e-01 | 5.22e-01 | 2.48e+00 | 1.31e-02 | 3.74e-02 | 1.06e-01 |
Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg01298514 | chr6:43769070 | CGI:chr6:43769895-43772115 | promoter | 7.84e-01 | 4.93e-01 | 1.38e+01 | 3.14e-43 | 6.17e-41 | 2.91e-01 |
| BRCA | cg18022921 | chr6:43769236 | CGI:chr6:43769895-43772115 | promoter | 6.77e-01 | 3.76e-01 | 1.39e+01 | 8.61e-44 | 2.12e-41 | 3.02e-01 |
| BRCA | cg00539360 | chr6:43769399 | CGI:chr6:43769895-43772115 | promoter | 6.87e-01 | 4.50e-01 | 1.36e+01 | 3.16e-42 | 4.45e-40 | 2.37e-01 |
Top |
Exon skipping events with PSI in TCGA for VEGFA |
| ∗Please access ExonSkipDB for exon skipping annotation. |
Landscape of exon skipping events across multiple cancer types. |
Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| HNSC | exon_skip_452243 | 4.15e-01 | 5.22e-01 | -4.41e+00 | 1.01e-05 | 1.05e-04 | -1.07e-01 |
| CHOL | exon_skip_452243 | 4.31e-01 | 6.01e-01 | -3.11e+00 | 1.85e-03 | 1.21e-02 | -1.70e-01 |
Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| BLCA | exon_skip_452243 | 4.56e-01 | 5.62e-01 | -2.81e+00 | 4.98e-03 | 2.32e-02 | -1.06e-01 |
Top |
RNA A-to-I editing events in TCGA for VEGFA |
| ∗Please access CAeditome for RNA editing annotation. |
Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for VEGFA |
TFs related to VEGFA.∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| SKCM | SRY | VEGFA | 3.49e+00 | 6.87e-03 | 4.59e+00 | 9.81e-01 | Female-biased |
| SKCM | ZNF418 | VEGFA | 1.90e+00 | 2.65e-05 | 4.61e+00 | 9.89e-01 | Female-biased |
VEGFA related gene.∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for VEGFA |
RBPs related to ES in VEGFA.∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| THYM | NOVA2 | exon_skip_452215 | 9.63e+00 | 9.86e-01 | 9.32e+00 | 1.09e-02 | Male-biased |
| READ | IGF2BP2 | exon_skip_452243 | 7.97e+00 | 9.80e-01 | 7.64e+00 | 1.10e-02 | Male-biased |
| READ | IGF2BP3 | exon_skip_452243 | 7.99e+00 | 9.80e-01 | 7.67e+00 | 1.12e-02 | Male-biased |
| PCPG | ZFP36 | exon_skip_452229 | 6.69e+00 | 3.30e-03 | 7.10e+00 | 9.84e-01 | Female-biased |
| MESO | ZFP36 | exon_skip_452232 | 6.54e+00 | 9.81e-01 | 5.97e+00 | 1.25e-03 | Male-biased |
VEGFA related ES.∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000112715 | Z95331.1,hsa-mir-106a,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | AC083843.2,hsa-mir-106a,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | CARS1-AS1,hsa-mir-205,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | AC083843.2,hsa-mir-205,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | CASK-AS1,hsa-mir-206,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | AC078795.1,hsa-mir-206,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | Z95331.1,hsa-mir-20b,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | AL356299.2,hsa-mir-497,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | Z95331.1,hsa-mir-497,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | Z95331.1,hsa-mir-504,VEGFA | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000112715 | Z95331.1,hsa-mir-93,VEGFA | Male-specific ceRNA | TCGA-HNSC |
Top |
Sex-biased eQTL regulation of gene |
Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12529279 | chr6:39204342:G:T | - | 0.246773682646075 | 0.0178557952435308 | KIRP | Female-baised eQTL |
| rs11968212 | chr6:39208610:G:A | - | 0.246773682646075 | 0.0178557952435308 | KIRP | Female-baised eQTL |
| rs236431 | chr6:36763020:A:G | - | 0.150587225790633 | 0.0379156801053068 | KIRP | Female-baised eQTL |
| rs3822969 | chr6:36752981:G:A | - | 0.191426107437738 | 1.74853807148869e-05 | LUSC | Female-baised eQTL |
| rs78905441 | chr6:42628151:G:T | - | 0.186574784584498 | 4.48821555764035e-05 | LUSC | Female-baised eQTL |
| rs4714616 | chr6:42648704:T:G | - | 0.186574784584498 | 4.48821555764035e-05 | LUSC | Female-baised eQTL |
| rs7771830 | chr6:42534951:G:A | - | 0.177506944940357 | 8.34239729231831e-05 | LUSC | Female-baised eQTL |
| rs78720743 | chr6:36751933:G:A | - | 0.162165824814966 | 0.000527971906541671 | LUSC | Female-baised eQTL |
| rs58298156 | chr6:36752327:G:A | - | 0.162165824814966 | 0.000527971906541671 | LUSC | Female-baised eQTL |
| rs59800485 | chr6:36752465:C:T | - | 0.162165824814966 | 0.000527971906541671 | LUSC | Female-baised eQTL |
| rs10484912 | chr6:42646106:T:C | - | 0.154134163331185 | 0.00193573731862039 | LUSC | Female-baised eQTL |
| rs13200755 | chr6:39184681:G:A | - | 0.145268142201731 | 0.00642006232918236 | STAD | Female-baised eQTL |
| rs10305525 | chr6:39088374:C:A | - | 0.0645229137336491 | 0.000406879815880136 | LGG | Female-baised eQTL |
| rs60678751 | chr6:39096167:G:A | - | 0.0664474581558109 | 0.00128367413387257 | LGG | Female-baised eQTL |
| rs2268636 | chr6:39083699:G:A | - | 0.0665663639203298 | 0.00146970821677011 | LGG | Female-baised eQTL |
| rs10305516 | chr6:39086813:C:G | - | 0.0646682748933289 | 0.00205021853594387 | LGG | Female-baised eQTL |
| rs2268634 | chr6:39084571:C:G | - | 0.0634283323023641 | 0.00263866893199107 | LGG | Female-baised eQTL |
| rs2268633 | chr6:39085217:G:C | - | 0.0632647980003333 | 0.00284890213069201 | LGG | Female-baised eQTL |
| rs59426516 | chr6:39116464:G:C | - | 0.0591331581150097 | 0.00715324659142179 | LGG | Female-baised eQTL |
| rs12665144 | chr6:39115512:C:T | - | 0.0566490251770102 | 0.0130684886819468 | LGG | Female-baised eQTL |
| rs12216216 | chr6:44244415:A:G | - | 0.0782980956556739 | 0.0142134189148313 | LGG | Female-baised eQTL |
| rs12202977 | chr6:44244638:G:C | - | 0.0782980956556739 | 0.0142134189148313 | LGG | Female-baised eQTL |
| rs3757280 | chr6:44245723:G:C | - | 0.0782980956556739 | 0.0142134189148313 | LGG | Female-baised eQTL |
| rs9367190 | chr6:44249917:C:A | - | 0.0782397240146612 | 0.0143365182195904 | LGG | Female-baised eQTL |
| rs9381303 | chr6:44249930:C:T | - | 0.0782397240146612 | 0.0143365182195904 | LGG | Female-baised eQTL |
| rs3187 | chr6:44254310:G:A | - | 0.0756936647052155 | 0.0184911272460121 | LGG | Female-baised eQTL |
| rs1570920 | chr6:44246699:C:G | - | 0.0719981116767728 | 0.0238134177689708 | LGG | Female-baised eQTL |
| rs2268635 | chr6:39083918:C:T | - | 0.0481616422323813 | 0.026441465123704 | LGG | Female-baised eQTL |
| rs9349648 | chr6:52893686:G:C | - | 0.166189572489509 | 0.0419914501032862 | KIRC | Female-baised eQTL |
| rs111352602 | chr6:36449886:C:T | - | 0.187605592471181 | 0.0206230585406493 | BLCA | Female-baised eQTL |
| rs916299 | chr6:36769815:C:T | - | 0.0819859274617801 | 0.0473508148877311 | COAD | Female-baised eQTL |
| rs916300 | chr6:36770271:G:A | - | 0.0819859274617801 | 0.0473508148877311 | COAD | Female-baised eQTL |
| rs916302 | chr6:36770362:T:C | - | 0.0819859274617801 | 0.0473508148877311 | COAD | Female-baised eQTL |
Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs76320213 | chr6:49942310:A:G | - | 0.144720116817126 | 0.0318673331266768 | PAAD | Male-baised eQTL |
| rs78200920 | chr6:49943243:C:A | - | 0.144720116817126 | 0.0318673331266768 | PAAD | Male-baised eQTL |
| rs12215337 | chr6:51008328:T:G | - | 0.108624492248974 | 0.01987007501185 | STAD | Male-baised eQTL |
| rs140613663 | chr6:37031705:T:C | - | 0.111127227270771 | 0.00825620070659045 | BLCA | Male-baised eQTL |
| rs74539719 | chr6:37047095:T:C | - | 0.107994323861673 | 0.0103454903357502 | BLCA | Male-baised eQTL |
| rs115291177 | chr6:37050340:G:A | - | 0.107994323861673 | 0.0103454903357502 | BLCA | Male-baised eQTL |
| rs56693599 | chr6:37049763:A:G | - | 0.107891474102177 | 0.0105138334814066 | BLCA | Male-baised eQTL |
| rs9382002 | chr6:51679815:G:C | - | 0.0730916253165371 | 0.0119015999371018 | BLCA | Male-baised eQTL |
| rs77467566 | chr6:37037850:G:A | - | 0.103591018303259 | 0.0137797190861508 | BLCA | Male-baised eQTL |
| rs73730518 | chr6:37038316:G:A | - | 0.103591018303259 | 0.0137797190861508 | BLCA | Male-baised eQTL |
| rs76878993 | chr6:37036451:A:G | - | 0.103518155396389 | 0.0138672836155232 | BLCA | Male-baised eQTL |
| rs76324291 | chr6:37044702:A:G | - | 0.103518155396389 | 0.0138672836155232 | BLCA | Male-baised eQTL |
| rs111724721 | chr6:37044112:G:A | - | 0.104850034226364 | 0.0139881887781296 | BLCA | Male-baised eQTL |
| rs2475801 | chr6:39946852:A:G | - | -0.0669714585309432 | 0.0148863041313289 | BLCA | Male-baised eQTL |
| rs4713933 | chr6:36158201:G:C | - | 0.0579772848142686 | 0.0408398491829964 | BLCA | Male-baised eQTL |
| rs2859133 | chr6:36148857:C:T | - | 0.0579582705962228 | 0.041519880603338 | BLCA | Male-baised eQTL |
| rs2815807 | chr6:36144646:C:T | - | 0.0575665054169321 | 0.0443342704359957 | BLCA | Male-baised eQTL |
| rs581216 | chr6:44911808:T:G | - | 0.105827886299703 | 0.00216260257492788 | COAD | Male-baised eQTL |
| rs3813502 | chr6:44153479:T:C | - | 0.0455592069389897 | 0.0203117795288667 | COAD | Male-baised eQTL |
| rs1041523 | chr6:44153533:C:T | - | 0.0455592069389897 | 0.0203117795288667 | COAD | Male-baised eQTL |
| rs9349413 | chr6:47543755:A:G | - | -0.045717963117141 | 0.0211454221170157 | COAD | Male-baised eQTL |
| rs302626 | chr6:39792176:T:C | - | -0.0660895884105129 | 0.0232084654614199 | COAD | Male-baised eQTL |
| rs12195738 | chr6:47615928:C:T | - | -0.0456504637479179 | 0.0241781844863424 | COAD | Male-baised eQTL |
| rs2987589 | chr6:39807458:A:G | - | -0.0692933890890506 | 0.0388798864101886 | COAD | Male-baised eQTL |
| rs2767727 | chr6:51408557:C:T | - | -0.0402453839534079 | 0.0478061795932475 | COAD | Male-baised eQTL |
Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg25343661 | chr6:43775444 | gene,exon | -0.494970383973877 | 9.05187929787806e-42 | -0.7973020029816009 | 2.7276053294141042e-45 | KIRP |
| cg18022921 | chr6:43769236 | promoter | -0.494529251402025 | 1.22950824058439e-41 | -0.7890135973464927 | 5.648847445607369e-44 | KIRP |
| cg00539360 | chr6:43769399 | promoter | -0.494529251402025 | 1.22950824058439e-41 | -0.7890135973464927 | 5.648847445607369e-44 | KIRP |
Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg25343661 | chr6:43775444 | gene,exon | -0.443866330293423 | 2.9843287004e-08 | -0.580519703894814 | 6.90933239537667e-11 | BLCA |
Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of VEGFA |
Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000112715 | VEGFA | C0001418 | Adenocarcinoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0002152 | Alloxan Diabetes | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0002395 | Alzheimer's Disease | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0003865 | Arthritis, Adjuvant-Induced | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0004096 | Asthma | 3 | CTD_human |
| ENSG00000112715 | VEGFA | C0004153 | Atherosclerosis | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0005586 | Bipolar Disorder | 2 | PSYGENET |
| ENSG00000112715 | VEGFA | C0006118 | Brain Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0006826 | Malignant Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0007102 | Malignant tumor of colon | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0007137 | Squamous cell carcinoma | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0007873 | Uterine Cervical Neoplasm | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0008677 | Bronchitis, Chronic | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0009375 | Colonic Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0010054 | Coronary Arteriosclerosis | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0010398 | Cruveilhier-Baumgarten Syndrome | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0011265 | Presenile dementia | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0011570 | Mental Depression | 5 | PSYGENET |
| ENSG00000112715 | VEGFA | C0011581 | Depressive disorder | 5 | PSYGENET |
| ENSG00000112715 | VEGFA | C0011616 | Contact Dermatitis | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0011853 | Diabetes Mellitus, Experimental | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0011881 | Diabetic Nephropathy | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0011884 | Diabetic Retinopathy | 3 | CTD_human |
| ENSG00000112715 | VEGFA | C0013366 | Dyschondroplasias | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0014170 | Endometrial Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0014556 | Epilepsy, Temporal Lobe | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0014558 | Uncinate Epilepsy | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0017636 | Glioblastoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0017667 | Nodular glomerulosclerosis | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0018671 | Head and Neck Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0018675 | Head Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0018798 | Congenital Heart Defects | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0018799 | Heart Diseases | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0018801 | Heart failure | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0018802 | Congestive heart failure | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0018923 | Hemangiosarcoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0020541 | Portal Hypertension | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0021368 | Inflammation | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0022660 | Kidney Failure, Acute | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0023186 | Learning Disorders | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0023212 | Left-Sided Heart Failure | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0023466 | Leukemia, Monocytic, Chronic | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0023470 | Myeloid Leukemia | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0023890 | Liver Cirrhosis | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0023893 | Liver Cirrhosis, Experimental | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0024115 | Lung diseases | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0024440 | Macular Edema, Cystoid | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0025237 | Melnick-Needles Syndrome | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0025261 | Memory Disorders | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0026760 | Multiple Epiphyseal Dysplasia | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0027055 | Myocardial Reperfusion Injury | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0027533 | Neck Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0027627 | Neoplasm Metastasis | 3 | CTD_human |
| ENSG00000112715 | VEGFA | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0027651 | Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0027659 | Neoplasms, Experimental | 3 | CTD_human |
| ENSG00000112715 | VEGFA | C0027686 | Pathologic Neovascularization | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0029422 | Osteochondrodysplasias | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0029463 | Osteosarcoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0030246 | Pustulosis of Palms and Soles | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0032927 | Precancerous Conditions | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0033578 | Prostatic Neoplasms | 4 | CTD_human |
| ENSG00000112715 | VEGFA | C0033687 | Proteinuria | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0033860 | Psoriasis | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0035228 | Respiratory Hypersensitivity | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0035309 | Retinal Diseases | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0035328 | Retinal Vein Occlusion | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0035412 | Rhabdomyosarcoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0036391 | Schwartz-Jampel Syndrome | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0038015 | Spondyloepiphyseal Dysplasia | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0038220 | Status Epilepticus | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0038358 | Gastric ulcer | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0038433 | Streptozotocin Diabetes | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0042076 | Urologic Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0085109 | Corneal Neovascularization | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0085605 | Liver Failure | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0086692 | Benign Neoplasm | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0151744 | Myocardial Ischemia | 5 | CTD_human |
| ENSG00000112715 | VEGFA | C0153633 | Malignant neoplasm of brain | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0162351 | Contact hypersensitivity | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0178540 | Cerebral Hypoxia-Ischemia | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0205643 | Carcinoma, Cribriform | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0206726 | gliosarcoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0233794 | Memory impairment | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0235527 | Heart Failure, Right-Sided | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0239946 | Fibrosis, Liver | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0242350 | Erectile dysfunction | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0242383 | Age related macular degeneration | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0270823 | Petit mal status | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0271051 | Macular retinal edema | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0271178 | Irvine-Gass Syndrome | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0276496 | Familial Alzheimer Disease (FAD) | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0278996 | Malignant Head and Neck Neoplasm | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0282313 | Condition, Preneoplastic | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0311335 | Grand Mal Status Epilepticus | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0334588 | Giant Cell Glioblastoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0342257 | Complications of Diabetes Mellitus | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0376358 | Malignant neoplasm of prostate | 4 | CTD_human |
| ENSG00000112715 | VEGFA | C0393672 | Epilepsy, Benign Psychomotor, Childhood | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0393682 | Epilepsy, Lateral Temporal | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0393734 | Complex Partial Status Epilepticus | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0432272 | Van Buchem disease | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0476089 | Endometrial Carcinoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0494463 | Alzheimer Disease, Late Onset | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0525045 | Mood Disorders | 2 | PSYGENET |
| ENSG00000112715 | VEGFA | C0546126 | Acute Confusional Senile Dementia | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0600518 | Choroidal Neovascularization | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0678807 | prenatal alcohol exposure | 1 | PSYGENET |
| ENSG00000112715 | VEGFA | C0746787 | Cancer of Neck | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0750900 | Alzheimer's Disease, Focal Onset | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0750901 | Alzheimer Disease, Early Onset | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0750974 | Brain Tumor, Primary | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751177 | Cancer of Head | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751262 | Adult Learning Disorders | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751263 | Learning Disturbance | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751265 | Learning Disabilities | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751292 | Age-Related Memory Disorders | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751293 | Memory Disorder, Semantic | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751294 | Memory Disorder, Spatial | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751295 | Memory Loss | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751522 | Status Epilepticus, Subclinical | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751523 | Non-Convulsive Status Epilepticus | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751524 | Simple Partial Status Epilepticus | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0751571 | Cancer of Urinary Tract | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0752304 | Hypoxic-Ischemic Encephalopathy | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0752305 | Anoxic-Ischemic Encephalopathy | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0752306 | Anoxia-Ischemia, Brain | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0752307 | Anoxia-Ischemia, Cerebral | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0752308 | Hypoxia-Ischemia, Brain | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0887833 | Carcinoma, Pancreatic Ductal | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0887900 | Upper Aerodigestive Tract Neoplasms | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C0971858 | Arthritis, Collagen-Induced | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C0993582 | Arthritis, Experimental | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C1269683 | Major Depressive Disorder | 5 | PSYGENET |
| ENSG00000112715 | VEGFA | C1330966 | Developmental Academic Disorder | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C1527390 | Neoplasms, Intracranial | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C1527411 | Thrombosis of retinal vein | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C1563937 | Atherogenesis | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C1565662 | Acute Kidney Insufficiency | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C1621958 | Glioblastoma Multiforme | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C1956346 | Coronary Artery Disease | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C1959583 | Myocardial Failure | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C1961112 | Heart Decompensation | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C2063866 | Depressive Disorder, Treatment-Resistant | 1 | PSYGENET |
| ENSG00000112715 | VEGFA | C2609414 | Acute kidney injury | 2 | CTD_human |
| ENSG00000112715 | VEGFA | C2676832 | MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1(finding) | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C2717961 | Thrombotic Microangiopathies | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C2931852 | Clear-cell metastatic renal cell carcinoma | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C2937358 | Cerebral Hemorrhage | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C3541456 | Spondyloepiphyseal Dysplasia Tarda, X-Linked | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C4048328 | cervical cancer | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
| ENSG00000112715 | VEGFA | C4551479 | Schwartz-Jampel Syndrome, Type 1 | 1 | CTD_human |